1 Department of Endocrinology, Clínica Universitaria de Navarra, 2 Metabolic Research Laboratory, and 3 Department of Histology and Pathology, University of Navarra, 31008 Pamplona, Spain
![]() |
ABSTRACT |
---|
The ability to ensure
continous availability of energy despite highly variable supplies in
the environment is a major determinant of the survival of all species.
In higher organisms, including mammals, the capacity to efficiently
store excess energy as triglycerides in adipocytes, from which stored
energy could be rapidly released for use at other sites, was developed.
To orchestrate the processes of energy storage and release, highly
integrated systems operating on several physiological levels have
evolved. The adipocyte is no longer considered a passive bystander,
because fat cells actively secrete many members of the cytokine family,
such as leptin, tumor necrosis factor-, and interleukin-6, among
other cytokine signals, which influence peripheral fuel storage,
mobilization, and combustion, as well as energy homeostasis. The
existence of a network of adipose tissue signaling pathways, arranged
in a hierarchical fashion, constitutes a metabolic repertoire that
enables the organism to adapt to a wide range of different metabolic
challenges, such as starvation, stress, infection, and short periods of
gross energy excess.
leptin; tumor necrosis factor-; interleukins; obesity; insulin
resistance
![]() |
OVERVIEW |
---|
Unraveling the diverse hormonal and neuroendocrine systems that regulate energy balance and body fat has been a long-standing challenge in biology, with obesity as an increasingly important public health focus (12). Adipose tissue is the body's largest energy reservoir. For example, an adult with 15 kg of body fat has >460 MJ (110,000 kcal) of lipid fuel stores, which could provide 8.37 MJ (2,000 kcal) daily for ~2 mo (75, 129). The primary role of adipocytes is to store triacylglycerol during periods of caloric excess and to mobilize this reserve when expenditure exceeds intake. Mature adipocytes are uniquely equipped to perform these functions. They possess the full complement of enzymes and regulatory proteins needed to carry out both lipolysis and de novo lipogenesis. In fat cells, the regulation of these processes is exquisitely responsive to hormones, cytokines, and other factors that are involved in energy metabolism (87). The ability to carry out these functions is acquired during embryonic development in preparation for the postnatal period, when an adipose energy reserve becomes necessary. Major expansion of the white adipocyte population is delayed until shortly after birth, although preadipocytes first appear late in embryonic life (22).
The present review will focus on the evidence for the synthesis and secretion by white adipocytes of endocrine, paracrine, and autocrine signals implicated in energy balance regulation, with special reference to cytokines. The interactions between these adipose tissue-derived mediators and other neuroendocrine pathways will be examined. Furthermore, the metabolic alterations in adipose tissue signaling leading to obesity and insulin resistance will be described.
![]() |
WHITE ADIPOSE TISSUE SIGNALS |
---|
Adipocytes, which vary enormously in size (20-200 µm in
diameter), are embedded in a connective tissue matrix and are uniquely adapted to store and release energy. Surplus energy is assimilated by
fat cells and stored as triglycerides in lipid droplets. To accommodate
the lipids, adipocytes are capable of changing their diameter 20-fold
and their volumes by several thousandfold. Because ~90% of the cell
volume is a lipid droplet, the nucleus and the thin cytoplasmic rim are
pushed to the periphery of the adipocytes. White adipose tissue is
actively involved in cell function regulation through a complex network
of endocrine, paracrine, and autocrine signals that influence the
response of many tissues, including hypothalamus, pancreas, liver,
skeletal muscle, kidneys, endothelium, and immune system, among others.
Until recently, the adipocyte has been considered to be only a passive
tissue for the storage of excess energy in the form of fat
(37). However, there is now compelling evidence that
adipocytes act as endocrine secretory cells (37, 143). It
has been shown that several hormones, growth factors, and cytokines are
actually expressed in white adipose tissue (Tables
1 and
2). In a dynamic view of the
adipocyte, a wide range of signals emanates from white adipose tissue,
such as leptin, tumor necrosis factor- (TNF-
), interleukin-6
(IL-6), and their respective soluble receptors. White adipose tissue
also secretes important regulators of lipoprotein metabolism, like lipoprotein lipase (LPL), apolipoprotein E (apoE), and cholesteryl ester transfer protein (CETP). The increasing number of products secreted by adipocytes also includes angiotensinogen, plasminogen activator inhibitor-1 (PAI-1), tissue factor, and transforming growth
factor-
(TGF-
). Nitric oxide synthase (NOS) has also been
reported to be expressed in rat white adipose tissue, indicating that
adipocytes are a potential source of NO production (131). Recently, evidence for an involvement of NO in both rat and human lipolysis has been published (3, 48). Interestingly,
leptin immunolabeling of white adipocytes exhibits an absolutely
superimposable staining pattern to that of inducible NOS (iNOS), as can
be observed in histological sections (Fig.
1 and
2). The role of insulin-like growth
factor I (IGF-I), glucocorticoids, and sex steroids in adipose tissue
proliferation, heterogeneity, and distribution is beginning to be
better understood. However, the influence of acylation-stimulating
protein (ASP), adipophilin, adipoQ, adipsin, monobutyrin, agouti
protein, and factors related to proinflammatory and immune processes
still remains to be fully elucidated (14). These
relationships show that white adipose tissue lies at the heart of a
network of autocrine, paracrine, and endocrine signals (Fig.
3). Through the existence of a network of
local and systemic signals, which interact with neuroendocrine
regulators, adipose tissue signaling pathways, arranged in a
hierarchical fashion, constitute one of the voices of the body that
enable the organism to adapt to a range of different metabolic
challenges, such as starvation, stress, and infection, as well as
periods of gross energy excess.
|
|
|
|
|
![]() |
ADIPOCYTE SECRETORY PRODUCTS AND THEIR METABOLIC EFFECTS |
---|
Adipocytes produce a great number of factors that serve as feedback signals to regulate adipose tisssue metabolism. Undoubtedly, the development of sophisticated molecular techniques has contributed to the identification of many of the secretory products of adipose tissue.
Adipsin
Adipsin is a serine protease secreted by fat cells. It was originally identified as a highly differentiation-dependent gene in 3T3-L1 adipocytes (21). Expression of adipsin is markedly downregulated in rodent obesities, probably as a consequence of increased concentrations of insulin and glucocorticoids (21). Sequence comparison revealed that both murine adipsin and human adipsin were identical to complement D (165), the initial and rate-limiting enzyme in the alternative complement pathway. It was shown that fat cells synthesize all of the proteins of the alternative complement pathway, namely factors C3, D (adipsin), and B (19). The proximal, nonlytic portion of the pathway is operative in adipose tissue, and, in vitro, the proteolytic cascade results in the production, among others, of biologically active C3a, Ba, and Bb (19). In cultured fat cell lines and other tissues, the activity of the alternative complement pathway requires stimulation by cytokines. However, the proximal pathway is fully functional in adipose tissue fragments, even without stimulation by cytokines, probably as a result of endogenous cytokine production. Further research is required to determine the primary functions and regulation of the alternative complement pathway in adipose tissue. The fact that partially acquired lipodystrophy is associated with constitutive activation of the alternative complement pathway points to a potential pathophysiological role of this pathway (19, 153).ASP
A 14-kDa serum protein resulting from the cleavage of the terminal arginine residue from C3a by plasma carboxypeptidases was named the acylation-stimulating protein (ASP) (41). Because C3a is the end product of the alternative complement pathway, of which factor D, adipsin, is a main component, it was proposed that it should be designated the "adipsin-ASP pathway" (148).Several roles for ASP in adipocyte metabolism have been proposed (41). It may be involved in the uptake and esterification of fatty acids to make triglycerides and facilitate fatty acid storage in the postprandial state. ASP increases after a fat-containing meal and stimulates triglyceride synthesis via diacylglycerol acyltransferase in adipocytes and fibroblasts. Although ASP is expressed by both preadipocytes and fibroblasts, ASP formation is, predominantly, a feature of mature and fully differentiated adipocytes (106). ASP stimulates triglyceride production to a greater extent than insulin, as well as having an additive effect with that of insulin (185). ASP also stimulates translocation of glucose transporters to the cell surface, probably by activation of the diacylglycerol-protein kinase C pathway (49). The fact that ASP is more potent in triglyceride synthesis stimulation supports a role for ASP in determining the rate at which fatty acids, derived from circulating triglycerides hydrolyzed by LPL, are esterified and stored in adipose tissue. Studies in ASP functional knockout mice support the putative role in triglyceride storage. Knockout mice have shown a delayed triglyceride clearance compared with wild-type animals, and this difference is further exaggerated in female mice. The delay in triglyceride clearance may be due to the effect on LPL of increased nonesterified fatty acid concentrations. Differences between adipose tissue depots have been detected, with greater degrees of ASP binding in subcutaneous compared with omental fat, in females compared with males, and in morbidly obese compared with nonobese individuals (111).
In contrast to rodent models, serum adipsin concentrations tend to be increased in obese human subjects, whereas adipsin secretion per adipocyte is normal (149). However, when we consider that adipsin production is not elevated in proportion to the increased fat cell size, in contrast to many other adipocyte proteins, the relatively lower ASP production could play a limiting role in the triglyceride synthesis rate as fat cells enlarge. Consistent with this reasoning, in vivo studies have shown that esterification of triglyceride fatty acids released by LPL is less efficient in obese than in lean subjects (39, 127). Further research will help to clarify whether the major role of ASP lies in regulating local triglyceride uptake by adipocytes, as well as whether adipose tissue contributes to the pool of serum ASP and thus to systemic triacylglycerol clearance. Furthermore, the exact nature of the participation of the adipsin-ASP pathway in fat cell size regulation, together with the concrete mechanism of action of ASP, still remains unknown.
Adipose Fatty Acid-Binding Protein
Fatty acid-binding proteins are abundant low-molecular-weight cytoplasmic proteins that are thought to be involved in the intracellular transport and metabolism of fatty acids (129). Different members of this gene family are expressed in a tissue-specific manner, with several tissues expressing more than one fatty acid- binding protein type. The adipose-specific fatty acid-binding protein, also known as aP2, is expressed during adipocyte differentiation and comprises up to 6% of cytosolic protein in the mature fat cell (152). Adipose fatty acid-binding protein has been shown to be involved in intracellular trafficking and targeting of fatty acids (183). This cytosolic adipose fatty acid-binding protein is postulated to shuttle fatty acids within the aqueous cytosol toward the membranes of the relevant intracellular organelles that are involved in triglyceride synthesis or fatty acid oxidation. This transfer is believed to occur via a collisional mechanism dependent on the interaction of organelle membrane phospholipids with the basic residues of aP2, resulting in partitioning of fatty acids to organelles for metabolic utilization (183). Knockout of aP2 (aP2Adipocyte Complement-Related Protein of 30 kDa
While a substraction cDNA library of mRNAs induced during differentiation of 3T3-L1 adipocytes was screened, an adipocyte complement-related protein of 30 kDa (Acrp30), another secretory protein belonging to the collectin family and expressed by fat cells, was found (67, 140). Acrp30, also called adipoQ, adiponectin, and adipose most abundant gene transcript 1 (apM1), is a relatively abundant serum protein that accounts for ~0.01% of the total plasmatic protein and shows similarity to complement factor C1q. Its expression is markedly reduced in adipose tissue of obese mice and humans (140). Its function is still unknown; however, like adipsin, its secretion is modulated by insulin, pointing to the possibility that its expression is regulated by the nutritional state. Adiponectin has been shown to suppress the attachment of monocytes to endothelial cells, which is an early event in atherosclerotic vascular change, thus suggesting a protective role against vascular damage. Furthermore, decreased plasma adiponectin concentrations may be an indicator of macroangiopathy in type 2 diabetic patients (66).Agouti Protein
The agouti gene encodes a secreted protein that acts in a paracrine manner to antagonize the melanocyte-stimulating hormone receptor, thereby regulating mouse coat color (102). Under normal circumstances, the agouti protein is expressed only in skin of mice. Dominant mutations in the agouti locus cause agouti to be expressed in all tissues, producing a syndrome consisting of yellow fur, obesity, hyperinsulinemia, and insulin resistance (86). Ectopic expression of agouti in transgenic mice reproduces this syndrome (86). In contrast to mice, the human agouti gene is normally expressed in adipose tissue and testis, suggesting a role for this protein in regulating adipose tissue function. The participation of the agouti protein in the development of insulin resistance has been proposed to be through increasing intracellular free calcium concentrations (191).Angiotensinogen
Angiotensinogen is primarily synthesized by the liver, although angiotensinogen mRNA is present in several tissues, including adipose tissue (76). Angiotensinogen is the substrate of renin in the renin-angiotensin system and is converted into angiotensin I, the precursor of angiotensin II. The physiological and pathological role of angiotensinogen gene expression in adipose tissue has not been completely elucidated. Angiotensin II has been suggested to influence adipocyte differentiation by interactions with angiotensin receptors, inducing fat cells to produce prostacyclin (24). Angiotensinogen expression is increased in obesity and, in contrast to the hepatic expression, is regulated by the nutritional status (41). During fasting, a decrease in mRNA above control has been observed, which increases upon refeeding. Furthermore, these changes in gene expression are paralleled by fluctuations in angiotensinogen secretion from isolated adipocytes. Angiotensinogen mRNA in both subcutaneous and omental fat correlates with the waist-to-hip ratio, with higher mRNA expression in the omental than in the subcutaneous adipose depot (171). Angiotensinogen may play a role in local adipose tissue blood flow and, hence, in rates of fatty acid reesterification (171). Thus, by affecting both substrate availability and preadipocyte differentiation, angiotensinogen is able to regulate adipose size in response to nutritional signals.PAI-1
PAI-1 is a member of the family of serine protease inhibitors or serpins. By inhibiting the tissue plasminogen activator, it is the main regulator of the endogenous fibrinolytic system (182). Therefore, increased concentrations of PAI-1 favor the development of thromboembolic complications. Among the multiple mechanisms that may explain the relationship between obesity and cardiovascular disease, disorders of the fibrinolytic system seem to play a key role (78). Elevated plasma concentrations of PAI-1 have been found in obese subjects. A close correlation with an abdominal pattern of adipose tissue distribution in both men and women, as well as a positive association with other components of the insulin resistance syndrome, have been reported (78, 146, 170). The mechanisms responsible for the increase in PAI-1 are not yet completely established. Expression and secretion of PAI-1 in adipose tissue from humans and rodents have been demonstrated. However, little is known about its regulation at the adipocyte level. Insulin and TGF-TGF-
TGF- mRNA expression has been shown to be higher in adipose tissue
of ob/ob and db/db mice compared with their lean
littermates (137). Moreover, this increase was due to
elevated expression of TGF-
mRNA by mature adipocytes and cells of
the stromal/vascular fraction. TNF-
contributes to the augmented
expression of TGF-
in adipose tissue of obese mice. In this sense,
chronically elevated TNF-
concentrations in adipose tissue of obese
individuals may act in an autocrine/paracrine manner and contribute to
increased TGF-
expression in obesity. The elevated gene expression
of TGF-
in adipose tissue may have broad implications in the
pathophysiology of obesity and its associated complications. TGF-
has been shown to increase preadipocyte cell proliferation. Thus the
augmented expression of TGF-
in the obese adipose tissue may
increase adipocyte precursor cell proliferation, thereby contributing
to the elevated cellularity of fat depots related to the obese
phenotype. Both obesity and type 2 diabetes are also associated with
characteristic long-term complications, including microvascular kidney
disease. Interestingly, overexpression of TGF-
in glomeruli has been
reported (41).
As mentioned before, TGF- stimulates PAI-1 biosynthesis in a variety
of cells, including adipocytes. Insulin failed to raise TGF-
mRNA
expression in lean mice, even though significantly increasing the
expression of PAI-1 mRNA in adipose tissue (137). Administration of TGF-
to lean mice has been shown to cause a 60-fold increase in plasmatic active PAI-1 and increased PAI-1 mRNA in
adipose tissue (137). The TGF-
-mediated induction of PAI-1 in 3T3-L1 adipocytes was considerably higher than the response of
these cells to TNF-
and insulin. Similarly, the greatest PAI-1 response in adipose tissue in in vivo studies was to TGF-
(36-fold), followed by TNF-
(9-fold), and insulin (7-fold) (136,
137).
Growth Hormone
Growth hormone (GH) is an important regulator of body mass throughout life (4, 14). It has been observed that GH deficiency in both children and adults is characterized by abnormal body composition, with increased fat mass and decreased lean muscle mass. GH-deficient subjects exhibit increased visceral and subcutaneous adipose tissue depots, which are partly normalized by GH therapy (2, 4). Whereas subcutaneous adipose tissue decreased by an average of 13%, visceral fat depots were reduced by 30%. In contrast, in patients with acromegaly, a reduced fat mass was observed to return to normal after treatment of the hormone excess by octreotide or pituitary surgery. Adipocytes have specific GH receptors, with the hormone exerting a variety of direct metabolic effects, such as inhibition of glucose uptake and stimulation of lipolysis, which may cause a net loss of stored lipids (2).Sex Steroids
Two enzymes of relevance to sex steroid metabolism are present in adipose tissue, 17 ![]() |
ADIPOCYTES AS A SOURCE OF CYTOKINES |
---|
Cytokines are defined as soluble proteins synthesized by immune or
nonimmune cells, which mediate intercellular communication by
transmitting information to target cells through receptor-ligand interactions. This class of mediators is represented by cytolytic, chemotactic, and immunoenhancing growth and differentiation factors. Many cytokines have physiological activities far beyond those originally discovered. A prominent role for cytokines in the regulation of energy balance has evolved from recent investigations.
Proinflammatory cytokines with potent actions in host defense, like
TNF- and IL-6, have also important effects on both lipid and glucose
metabolism (53, 111).
IL-6
The term interleukin originally described a leukocyte-derived protein with activity for other leukocytes. It is now understood that both immune and nonimmune cells synthesize interleukins and other cytokines, which have diverse biological activities.Interleukin-6 expression in adipose tissue. Interestingly, production of IL-6, as well as systemic concentrations, has been shown to be positively correlated with body mass index (175). As much as a third of total circulating concentrations of IL-6 has been estimated to originate from adipose tissue (110, 184). In this sense, IL-6 may be both an autocrine and a paracrine regulator of adipocyte function. Omental fat produces threefold more IL-6 than subcutaneous adipose tissue, and adipocytes isolated from the omental depot also secrete more IL-6 than fat cells from the subcutaneous depot (40). Although it has now been clearly established that adipocytes themselves secrete IL-6 on a per lipid weight or per fat cell basis, this cell type accounts for only 10% of the total adipose tissue production, as evidenced by determination of IL-6 released by intact adipose tissue fragments and isolated adipocytes prepared from omental and subcutaneous fat depots (40). Thus other cells within the adipose tissue also contribute to the high release of IL-6. This is not surprising, because IL-6 is a multifunctional cytokine produced by many different cell types, including immune cells, fibroblasts, stromal-vascular cells, endothelial cells, myocytes, and a variety of endocrine cells (172). The amount of IL-6 produced by adipose tissue is similar to or greater than that reported for a variety of other tissues and cells, with the concentrations of IL-6 accumulating in adipose tissue or cell incubations (up to 75 ng/ml) being well within the range to elicit biological effects (51). Regardless of the cellular source of IL-6, it is interesting to note that adipose tissue may be an important source for the increased serum concentrations of IL-6 observed in obesity, with depot-specific differences in terms of both quantitative contribution to the serum pool and qualitative participation in lipid metabolism. Because the venous drainage from omental adipose tissue flows directly into the liver, the metabolic impact of IL-6 release from this fat depot may be of particular importance. In this sense, it has been shown that IL-6 increases hepatic triglyceride secretion (116) and may, therefore, contribute to the hypertriglyceridemia associated with visceral obesity.
IL-6 is secreted by adipose tissue under basal conditions. It has been shown that TNF-IL-6 receptors. Class I cytokine receptors are known to act through Janus kinases (JAK) and signal transducers and activators of transcription (STAT). JAK proteins are associated with membrane-proximal sequences of the receptor intracellular domain, which is phosphorylated upon ligand binding. The phosphorylated intracellular domain then provides a binding site for a STAT protein, which is activated, translocates to the nucleus, and stimulates transcription. The biological activities of IL-6 are initiated by binding to a high-affinity receptor complex consisting of two membrane glycoproteins (160). The IL-6 receptor (IL-6R), the 80-kDa ligand-binding component, binds IL-6 with low affinity, but the 130-kDa signal-transducing component, gp130, although not binding free IL-6, is required for high-affinity binding of gp80-bound IL-6. It has been reported that IL-6-type cytokines use tyrosine kinases of the JAK family for signal transduction (71). Dimerization of the intracellular domains of two gp130 molecules brings the receptor-associated JAKs (JAK1, JAK2, and Tyk2) into close proximity, leading to activation via inter- or intramolecular phosphorylation and activation. Specific STAT proteins are recruited to the stimulated receptor complexes and are activated by direct phosphorylation by receptor-asscociated JAKs. The leukemia inhibitory factor (LIF), a member of the IL-6 family of cytokines, has been shown to activate the JAK/STAT pathway (71). After the activation of the signal transduction receptor gp130, LIF induces a rapid tyrosine phosphorylation of JAK1, JAK2, Tyk2, STAT1, and STAT3.
A soluble form of IL-6R (IL-6Rs), apparently arising from proteolytic cleavage of the membrane-bound receptor and with a molecular mass of ~50 kDa, has been found (157). The recombinant IL-6Rs has been shown to increase the activity of IL-6 as a result of the binding of the IL-6/IL-6Rs complex to the membrane-bound gp130 (160). Elevated concentrations of IL-6 have been suggested to be associated with increased production of IL-6Rs (133). Recently, evidence for a soluble form of the gp130 receptor, which may exert antagonist properties, has also been reported (186). In humans, subcutaneous adipose tissue has been shown to release IL-6 but not soluble receptors (109, 110). Therefore, a regulatory role for adipocytes in the bioavailability of cytokines has been put forward (111). However, neither the functional significance nor the regulation of soluble receptors is clearly understood.Biological effects of IL-6.
IL-6 decreases adipose tissue LPL activity and has been implicated in
the fat depletion taking place during cancer cachexia and other wasting
disorders (51, 158). Like TNF-, IL-6 has potent effects
on adipose tissue, as evidenced by the fact that neutralization of this
cytokine decreases the loss of adipose tissue during cachexia
(158). It seems unlikely that this effect is mediated
solely by the documented ability of IL-6 to downregulate LPL activity,
implying that IL-6 exerts other actions on adipocyte metabolism. IL-6
is considered to be an inflammatory mediator as well as a
stress-induced cytokine (189). It has pleiotropic effects
on a variety of tissues, including downregulation of adipocyte LPL,
stimulation of acute-phase protein synthesis, increase in the activity
of the hypothalamic-pituitary axis (HPA), and thermogenesis, consistent
with the candidate role of corticotropin-releasing hormone (CRH) as a
common mediator of both of these actions.
TNF-
TNF- expression in adipose tissue.
Hotamisligil et al. (65) were the first to describe
adipose expression of TNF-
mRNA in different rodent models of
obesity. Clinical studies have also revealed expression of TNF mRNA in human adipose tissue (62, 68, 81). Subcutaneous fat depots exhibit a 1.67-fold higher TNF-
mRNA expression than omental fat
depots (68). The amount of TNF-
mRNA is positively
correlated with body adiposity and decreases in obese subjects after
weight loss (112). TNF-
mRNA expression is also closely
correlated with hyperinsulinemia, showing positive associations with
fasting insulin and triglyceride concentrations (62).
Expression pattern of TNF- receptors.
In addition to measuring TNF-
mRNA, it is also important to study
the expression pattern of TNF receptors (TNFR) in adipose tissue.
TNF-
interacts with two cell-surface receptors, p55 (p60 in humans)
and p75 (p80 in humans) (52). Regulation of the expression of these two receptors seems to underlie separate mechanisms, because
they present different cellular and tissue distribution patterns. The
p60 TNFR appears to be primarily involved in insulin receptor signaling
and glucose transport (121), and the p80 TNFR has been
shown to be involved in the pathogenesis of TNF-induced insulin
resistance (61, 96). The lack of p75 TNFR in diet-induced obese mice leads to body weight loss with improved insulin
concentrations and sensitivity (142). Obese mice deficient
in p55 TNFR showed slightly elevated insulin concentrations after 3 mo
of a high-fat diet, whereas mice lacking both receptors were
significantly hyperinsulinemic during the 4 mo of high-fat feeding
(142). The researchers concluded that TNFR may be required
for glucose homeostasis but do not exert a critical role in the
development of insulin resistance. Conversely, the lack of p55 TNFR in
ob/ob mice has been shown to cause an improvement of insulin
sensitivity, whereas a lack of the p75 TNFR alone did not alter insulin
action but potentiated the effect of p55 TNFR deficiency in animals
deficient in both receptors (168). Subsequent studies
performed in preadipocyte cell lines from these knockout mice confirmed
that TNF-induced insulin resistance, as well as alterations in the
adipogenic program, can be attributed predominantly to the actions of
the p55 TNFR (69).
Biological effects of TNF-.
TNF-
has pronounced catabolic effects in adipose tissue
(69). It suppresses LPL at the mRNA and protein levels, as
reported in many in vivo and in vitro studies. TNF-
inhibits the
expression of the two master regulators of adipose differentiation, the
transcription factor CCAAT/enhancer binding protein-
(CEBP
) and
the nuclear receptor peroxisome proliferator-activated receptor-
2
(PPAR
2) (156, 184). This suppression may result in the
subsequent downregulation of many adipocyte-specific proteins, such as
LPL, aP2, fatty acid synthetase, acetyl-CoA carboxylase,
glycerol-3-phosphate dehydrogenase (GPDH), and GLUT-4 among
others. Furthermore, mature adipocytes are stimulated to mobilize
lipids upon TNF-
exposure, possibly via hormone-sensitive lipase
activation (56). Among the multiple properties of TNF-
,
the antiadipogenic effect is especially relevant, because adipose
conversion of fat cell precursors is potently inhibited by TNF-
(122). Moreover, chronic treatment of mature fat cells
with TNF-
has been shown to lead to a reversion of the adipocyte
phenotype back to a fibroblast-like morphology (122).
Leptin
A major development in energy balance regulation has come with the discovery in 1994 of leptin, the protein product of the ob gene (196). The initial concept was that leptin informs the brain about the abundance of body fat, thereby allowing feeding behavior, metabolism, and endocrine physiology to be coupled to the nutritional state of the organism (1, 44). Leptin consists of four antiparallelLeptin expression in adipose tissue. Leptin biosynthesis and release are governed by paracrine, endocrine, and neuroendocrine signals that impinge on the adipocyte (1, 44, 111, 166). Because leptin is secreted by fat cells in proportion to body fat stores, it has the potential to play a key regulatory role in fuel homeostasis (166). As would be predicted of a factor involved in energy balance, expression of the ob gene is subject to nutritional regulation. Fasting induces a fall in the level of ob mRNA, which is rapidly reversed on refeeding, and circulating leptin levels change in parallel with tissue mRNA (44, 166). Glucosamine infusion increases leptin expression in adipose tissue and induces de novo leptin synthesis in rat skeletal muscle (179). Glucose infusion and lipid infusion have similar effects on leptin expression in adipose tissue and muscle, raising the possibility that leptin acts as a sensor of nutrient flux in these tissues.
Evidence for a direct autocrine/paracrine effect of leptin on the lipolytic activity of isolated adipocytes has recently been reported (43). In addition, leptin has been shown to repress acetyl-CoA carboxylase gene expression, fatty acid synthesis, and lipid synthesis; these are biochemical reactions that contribute to lipid accumulation without the participation of centrally mediated pathways (145, 180, 181). Thus leptin is involved in the direct regulation of adipose tissue metabolism by both inhibiting lipogenesis and stimulating lipolysis (44). Insulin stimulates ob gene expression, as do estrogens and glucocorticoids, with the effects of the latter being maintained during chronic treatment. Although plasma leptin, thyroid-stimulating hormone (TSH), and adiposity correlate in euthyroid patients, there are conflicting reports on the effect of hypo- and hyperthyroidism on ob gene expression (1). Androgens and GH decrease ob gene expression (1, 6, 44). Similarly, cold exposure induces a sympathetically mediated suppression of the ob gene, leading to a rapid decrease in both ob mRNA and serum leptin concentrations (166). Plasma leptin concentrations and adipocyte ob mRNA expression are strongly correlated with estimates of obesity, and total fat mass, percent body fat, and body mass index are the best predictors (1). Leptin mRNA shows higher expression in subcutaneous than in omental adipocytes (112). In addition, a striking sexual dimorphism is evident in both ob mRNA expression and circulating leptin concentrations, with almost twofold higher leptin concentrations in women (44). Adipocyte size is an important determinant of leptin synthesis, because larger fat cells contain more leptin than smaller adipocytes from the same individual (1, 23). However, it is not known whether increased triglyceride contents, lipid metabolites, or mechanical factors associated with augmented adipocyte size influence leptin expression. It has been shown that a proportional increase in adipocyte size is insufficient to explain the sex- and site-specific differences observed (112). Omental fat depots represent a more rapidly mobilizable source of energy in the form of free fatty acids, particularly in response to stress hormones. Thus the observation of increased leptin mRNA in subcutaneous compared with omental adipocytes may imply that omental adipose tissue is a less important contributor to the long-term feedback loop controlling appetite and metabolic rate than subcutaneous adipose tissue. Although this property of omental fat may be advantageous in allowing a more efficient use of available calories in times of alternating food scarcity and plenty, in modern sedentary humans with an ensured food supply, reduced leptin mRNA expression, and hence leptin production from omental adipocytes, may contribute to the high prevalence of central obesity with its associated pathological consequences. Some researchers attribute the observed gender differences to the stimulating role of estrogens and the suppressive effect of circulating androgens, but other investigators have not been able to ascribe the sexual dimorphism to sex hormones (44, 103). Further studies will be required to address the molecular basis for and physiological consequences of depot- and sex-specific variation in ob mRNA expression in humans. Cell-autonomous factors such as intracellular metabolites, signaling molecules, or transcription factors act as other major links between adipocyte size and leptin gene expression (151). Like many other adipocyte genes, the ob gene promoter is positively regulated through a functional binding site for CEBPLeptin receptors. Consistent with leptin's pleiotropic effects, leptin receptors (OB-R) exhibit an almost universal distribution. The OB-R belong to the class I cytokine receptor family, which includes the receptors of IL-6, LIF, GSCF, and gp130 (1, 161). OB-R are produced in several alternatively spliced forms, designated OB-Ra, OB-Rb, OB-Rc, OB-Rd, and OB-Re. The receptors share an identical extracellular ligand-binding domain of 840 amino acids at the amino terminus, as well as a transmembrane domain of 34 amino acids, but they differ at the carboxy terminus. A variable intracellular domain, characteristic for each of the five receptor isoforms, has been identified. Only the full-length isoform, the OB-Rb, is believed to be involved in leptin signaling and is considered to be the functional receptor. Recent reports have shown that activation of OB-Rb, and to a lesser extent OB-Ra, mediates ligand-induced activation of both JAK and STAT proteins (1, 8). The extracellular and cytoplasmic regions of OB-R and gp130 possess conserved motifs and are closely related to each other. OB-R and gp130 appear to mediate overlapping but distinct cytoplasmic signals (114). Furthermore, recent reports have shown that OB-R stimulate transcription via IL-6 and hematopoietin receptor-responsive elements (8). Thus OB-R share, at least in part, some of the signaling pathways characteristic of the class I cytokine receptor family. The lack of the full-length OB-R has been shown to be responsible for the db/db mouse obesity phenotype and the fatty mutation (8, 161).
The OB-Re, which lacks the intracellular and transmembrane domains, circulates as a soluble receptor (93). Secreted extracellular domains of cytokine receptors are known to function as specific binding proteins (58). In mice, it has been observed that the putative soluble isoform, OB-Re, is produced at a level that is sufficiently high to act as a buffering system for free circulating leptin (97).Biological effects of leptin. Leptin has diverse effects in addition to appetite and body weight regulation. Many cytokines, originally isolated on the basis of particular biological actions, have subsequently been shown to be capable of stimulating a variety of biological responses in a wide spectrum of cell types. Thus leptin shares with other cytokines an extreme functional pleiotropy and has been shown to be involved in quite diverse physiological functions, such as reproduction (17), hematopoiesis (20), angiogenesis (147), immune responsiveness (98), blood pressure control (42), and bone formation (30).
It has been shown that leptin is necessary for maturation of the reproductive axis, as evidenced by its ability to restore puberty and fertility in ob/ob mice, accelerate puberty in wild-type mice, and facilitate reproductive behavior in rodents (1). Therefore, leptin signals the adequacy of energy stores for reproduction by interacting with different target organs in the hypothalamic-pituitary-gonadal axis (44). The functional OB-R has been shown to be capable of signaling for cell survival, proliferation, and differentiation into macrophages (20, 46). In addition, leptin appears to be able to enhance the production of cytokines in macrophages and to increase the attachment and subsequent receptor-mediated process of phagocytosis (46). This activity may be mediated by an upregulation of macrophage receptors or by increased phagocytic activity. In this sense, a role for leukocyte adhesion receptors in maintenance of normal body weight and adiposity has recently been described (28). In addition, leptin has a direct proliferative effect on T cells, showing an adaptive response of this hormone to enhance the immune competence of the organism against the immunosuppression associated with starvation (98). Leptin has to be included in the list of angiogenic factors secreted by adipose tissue, because it has been shown to cause cultured endothelial cells to aggregate, form tubes, and display a reticular array reminiscent of tissue vasculature (147). It has also been observed that leptin accelerates wound healing, a process depending on blood vessel growth. Regarding blood pressure homeostasis, leptin appears to have a balanced effect, with a pressor response attributable to sympathetic activation and a depressor response attributable to NO release (42). Therefore, leptin is involved in the control of vascular tone by simultaneously producing a neurogenic pressor action and an opposing NO-mediated depressor effect. In this sense, leptin may be one of the factors underlying the association of obesity with increased incidence of hypertension and cardiovascular mortality. A recent study identified leptin as a potent inhibitor of bone formation, acting through the central nervous system (30). Despite suffering from hypogonadism and hypercortisolism, known inducers of increased osteoclast number and bone resorption activity, leptin-deficient and OB-R-deficient mice exhibit a high bone mass phenotype. Interestingly, this phenotype is not secondary to obesity but is directly related to the lack of leptin signaling. Intracerebroventricular infusion of leptin to ob/ob and wild-type mice was followed by a significant bone mass reduction (30). ![]() |
CROSS TALK AMONG ADIPOCYTE-DERIVED CYTOKINES |
---|
TNF-, IL-6, and leptin share both structural and functional
similarities with other cytokines, including receptor homology, signaling via the JAK/STAT system, growth factor properties, and circulation in plasma, either in the free form or bound to specific serum proteins (7, 8, 44, 101, 161, 193). All three cytokines are expressed and released by adipocytes, exerting a key role
in fat mass control. TNF-
induces the release of both IL-6 and
leptin from adipose tissue (54, 138). Knockout mice for
the TNF-
gene showed a hypoleptinemia compared with wild-type mice
(85). Apparently, TNF-
induces leptin production
through the p55 TNF receptor (36). All three cytokines,
TNF-
, IL-6, and leptin, are closely interrelated as well as
influencing and being regulated by other hormones and the sympathetic
nervous system (Fig. 4) (111, 124,
194).
|
Proinflammatory cytokines have been shown to play a major role in the
initiation of the sepsis syndrome, with the amount and speed of their
release correlating with the occurrence of septic shock and,
eventually, with mortality (16). However, TNF- and IL-1
are seldom found in the circulation of septic patients. It has been
proposed that enhanced production of endogenous inhibitors of these
cytokines, such as soluble TNFR and IL-1 receptor antagonist, as well
as increased secretion of the anti-inflammatory cytokine IL-10, may be
important host defense mechanisms to attenuate concurrent proinflammatory cytokine activity during sepsis. Leptin synthesis is
stimulated by infection, endotoxin, and cytokines such as TNF-
, LIF,
and IL-1 (54, 74, 138). The rise in leptin concentrations as a result of cytokine increase may contribute to the anorexia and
weight loss accompanying these inflammatory conditions. An independent
association for leptin with IL-1 receptor antagonist and IL-10 in
sepsis and septic shock has been described (5). In
addition, leptin and IL-6 have been shown to be independent predictors
of death in both study groups. Because patients with sepsis and septic
shock have higher plasma concentrations (2.3- and 4.2-fold,
respectively) than those expected on the basis of their fat mass, it
has been postulated that, in this case, circulating leptin does not
signal the magnitude of energy stores to the hypothalamus but works
rather as a stress-related peptide. Survivors of severe sepsis and
septic shock exhibited leptin concentrations 1.3- and 1.6-fold greater
than nonsurvivors in each group (5). Thus the leptin
response may be related to the extent of activation of the immune
system and may serve as a marker of the severity and outcome of septic
patients (5), because leptin has been shown to stimulate
proliferation of lymphohematopoetic cells and phagocytic activity of
macrophages (46).
![]() |
CYTOKINES IN ENERGY REGULATION |
---|
Although adipose tissue consumes little oxygen relative to other organs, it is an exceptionally efficient participant in the regulation of fuel selection in whole body physiology (38). Adipose tissue has the ability to regulate its metabolism, cell size, and cell number through the production of autocrine, paracrine, and endocrine signals. By participating in food intake regulation, the adipocyte literally controls the substrate flow available for storage of triglycerides.
Obesity results from both quantitative and qualitative changes at the
adipose tissue level. An excess of adipose tissue frequently includes
both hyperplasic and hypertrophic development (14, 22).
This circumstance tends to exacerbate the overproduction of cytokines
and other mediators, with the potential of exerting their effects both
locally and systemically, and thus promoting the pathophysiological
complications associated with increased fat mass (Fig.
5). As mentioned above, the efficiency of
fat deposition is affected by local secretion of adipocyte-derived
factors, which influence insulin signaling, decrease lipogenic gene
expression, increase lipolysis, control blood flow, and regulate
intracellular triglyceride synthesis. The mechanisms that lead to
obesity are complex and involve multiple cytokines, hormones, and
growth factors. The fact that TNF-, leptin, IL-6, insulin, PAI-1,
TGF-
, and the like are elevated in obesity and induce other
adipocyte-derived products in both plasma and adipose tissue reveals
the participation of a highly intricate network of signals in the
regulation of obesity. Undoubtedly, there are many other mechanisms and
factors that regulate the level of energy stores by modulating the
deposition and mobilization of adipose triglyceride pools and that need
to be uncovered.
|
![]() |
EFFECTS OF CYTOKINES ON INSULIN SIGNALING |
---|
There is growing experimental evidence from animal studies that
TNF- plays a key role in the pathogenesis of insulin resistance associated with obesity (69). Hotamisligil et al.
(65) were the first to report a close relationship between
increased adipose TNF-
expression and features of insulin resistance
in rodent models of obesity and type 2 diabetes mellitus
(65). In obese fa/fa rats, insulin resistance
could be reversed by infusion of a TNF-
-neutralizing IgG fusion
protein containing soluble TNFR domains. Subsequent investigations
showed that TNF-
interferes with the tyrosine phosphorylation of the
insulin receptor in Fao hepatocytes and 3T3 cells (35).
Further experiments demonstrated that TNF-
induces phosphorylation
of insulin receptor substrate-1 (IRS-1) at serine residues and that
serine-phosphorylated IRS-1 operates as an inhibitor of insulin
receptor activity (64, 80). By use of a fibroblast cell
line overexpressing the human insulin receptor, a role for
phosphotyrosine phosphatases in the TNF-mediated inhibition of insulin
signaling has been postulated (90). Furthermore, in
response to acute insulin stimulation after cellular TNF-
exposure,
a normal tyrosine phosphorylation of the insulin receptor and IRS-1,
together with a reduced expression of proteins involved in insulin
action, such as IRS-1 and GLUT-4, has been reported, representing a
plausible explanation for the observed insulin resistance of glucose
transport (155). The potential role of IRS-2 in
TNF-induced insulin resistance has yielded conflicting results.
Although in hepatoma cells and brown adipocytes IRS-2 has been shown to
be involved in the induction of insulin resistance through TNF-
(120), in cultured white fat cells, IRS-2 did not mediate
the inhibition of insulin signaling by TNF-
(121).
So far, most studies on the mechanisms of insulin resistance related to
TNF- have been carried out in animal models. However, whether this
holds true for humans has not been completely elucidated. A rapid
inhibition of insulin signaling at the phosphatidylinositol (PI)
3-kinase level by TNF-
treatment and a concomitant inhibition of
insulin-stimulated glucose transport in isolated human adipocytes have
been reported (69, 96). The effect of TNF-
was
correlated with an inhibition of tyrosine phosphorylation of IRS-1 with
unaltered autophosphorylation of the insulin receptor
-subunit (Fig.
6). Long-term exposure to TNF-
in
vitro of differentiated human adipocytes resulted in a dramatic
reduction of GLUT-4, whereas GLUT-1 expression was upregulated
(56). On the contrary, intravenous administration of a
recombinant-engineered human TNF-neutralizing antibody to patients with
type 2 diabetes mellitus did not alter fasting glucose and insulin
concentrations. Furthermore, glucose clearance during intravenous
insulin sensitivity tests remained unaffected by the TNF-neutralizing
antibody treatment, arguing against a prominent role of circulating TNF
in the development of insulin resistance in humans (118).
|
Although the mechanisms of TNF-mediated insulin resistance are only
incompletely understood, TNF- is a potentially attractive target for
pharmacological intervention aimed at protecting against obesity-induced insulin resistance (124, 169). Numerous
strategies are currently in progress in controlled clinical trials to
suppress the production or activity of TNF-
in a variety of diseases
(33). It will be interesting to establish whether
suppression of TNF-
improves insulin sensitivity in humans and how
it influences adipose tissue metabolism.
Ligand binding to the OB-Rb results in the activation of JAK2 by transphosphorylation and the subsequent tyrosine phosphorylation of tyrosine residues on the intracellular OB-Rb (7, 11). In general, tyrosine phosphorylation of cytokine and growth factor receptors activates intracellular signals by recruiting specific signaling proteins with specialized phosphotyrosine-binding domains called SH2 domains. Thus the two OB-Rb tyrosine residues that are phosphorylated during receptor activation mediate distinct signaling pathways, with SHP-2 binding to Tyr 985 positively regulating the extracellular factor-regulated kinase (ERK)-c-fos pathway, and STAT3 binding to Tyr1138 mediating the inhibitory SOCS-3 pathway (7, 10, 11, 94). It has been shown that SOCS-3 is a leptin-regulated inhibitor of proximal leptin signaling in vivo, and, therefore, excessive SOCS-3 activity in leptin-responsive cells is a potential mechanism for leptin resistance (94).
Leptin is not only a central regulator of body fat mass by decreasing food intake and increasing energy expenditure, but it also could be involved in insulin resistance induction, possibly via peripheral mechanisms of action (44). Recent reports suggest complex interactions between the leptin and insulin signaling pathways that can potentially lead to differential modification of the metabolic effects of insulin exerted through insulin receptor substrates (IRS-1 and IRS-2). In fact, leptin can act through some components of the insulin-signaling cascade, such as IRS-1 and IRS-2, PI 3-kinase, and MAPK, and can modify insulin-induced changes in gene expression in vitro and in vivo (84, 159). It has been shown that, in Fao cells, leptin alone has no effect on the insulin-signaling pathway, but leptin pretreatment transiently enhances insulin-induced tyrosine phosphorylation and PI 3-kinase binding to IRS-1 while producing an inhibition of tyrosine phosphorylation and PI 3-kinase binding to IRS-2 (159). Leptin alone also induces serine phosphorylation of Akt and glycogen synthase 3, but to a lesser extent than insulin, and the combination of these hormones is not additive. A divergence of leptin effects on insulin-stimulated IRS-1 and IRS-2-mediated signaling and on three downstream kinases suggests a complex and multidimensional interaction between these two hormonal signaling systems. Leptin rapidly activates signaling pathways directly at the level of insulin-sensitive tissues through the OB-Rb, and these pathways overlap with, but are distinct from, those engaged by insulin (84).
TNF- has been shown to induce a rapid release of leptin from white
adipose tissue (54, 85). Human studies have yielded conflicting results. Infusion of TNF-
to patients was followed by a
rapid rise in serum leptin concentrations (198), whereas long-term exposure of cultured human adipocytes to TNF-
resulted in
a reduction of leptin mRNA levels (50). Therefore, further studies are needed to clarify the exact relationship between TNF-
and leptin in the context of insulin resistance.
It has recently been shown that, in the presence of markedly reduced insulin action in skeletal muscle, glucose is partly shunted to white adipose tissue (83). Thus selective insulin resistance in muscle promotes redistribution of substrates to adipose tissue, thereby contributing to increased adiposity and development of the prediabetic syndrome. In obese patients, increased production of nonesterified fatty acids and cytokines contributes to insulin resistance. The changes in systemic metabolism that lead to insulin resistance have been reported to develop in an attempt to prevent further weight gain (32). Mobilization of energy stores, impaired insulin signaling, increased lipolysis, and central neuroendocrine effects, such as HPA activation, may be adaptive under certain circumstances, including the early stages of fuel storage and in acute inflammation, whereas such changes may become maladaptive during sustained weight gain (111). In this sense, IL-6 reduces LPL activity, reducing fuel storage and thereby limiting weight gain on the one hand, but IL-6 also increases hepatic synthesis of procoagulant molecules, contributing to dyslipidemia on the other hand.
The receptor complex mediating the biological activities of IL-6 consists of two distinct membrane-bound glycoproteins, an 80-kDa cognate receptor (IL-6R) and a 130-kDa signal-transducing element (gp130). Cellular activation by IL-6 requires binding to its cognate receptor and the resulting dimerization of gp130 (77). In addition to the membrane-bound receptor, the IL-6Rs binds IL-6 with a similar affinity to that of the cognate receptor and prolongs its plasma half-life. The IL-6R/IL-6Rs complex is capable of activating cells via interaction with membrane-bound gp130 (Fig. 6). This feature makes the IL-6R/IL-6Rs complex an agonist for cell types that, although they express gp130, would not inherently respond to IL-6 alone (77). Hence, the IL-6Rs has the ability to widen the repertoire of cell types that are responsive to IL-6. Signaling is facilitated through the homodimerization of gp130 to the ligand-receptor complex. This mediates phosphorylation of gp130-associated JAKs, which facilitates the docking of STAT1/STAT3 factors to gp130 and their phosphorylation. IL-6 also activates the Ras-Raf signaling cascade, which regulates phosphorylation of MAPK and ultimately activation of transcription factors such as CEBP (77).
![]() |
CROSS TALK WITH NEUROENDOCRINE PATHWAYS |
---|
Adipose tissue is an endocrine organ influencing many aspects of
fuel metabolism through a network of local and systemic signals that
interact with the established neuroendocrine regulators. Cytokine
production appears to be acutely regulated by sympathetic stimulation.
Catecholamines have been shown to regulate the production of leptin,
IL-6, and TNF- (111). Isoprenaline infusions in humans had a stimulatory effect on circulating IL-6 concentrations, but little
or no appreciable change was observed in TNF-
. Conversely, catecholamines and synthetic adrenergic agonists have been demonstrated to rapidly suppress leptin mRNA levels in mouse adipocytes
(166), whereas in humans, isoprenaline produced an acute
suppression of plasma leptin concurrently with an increased lipolytic
activity (125).
It has been reported that IL-6 directly stimulates adrenal cortisol release in addition to stimulating hypothalamic CRH and pituitary ACTH release (72). Adipose tissue IL-6 may, therefore, act as a feedforward regulator of HPA function. Cortisol suppression of adipose IL-6 production may serve as a feedback inhibitor of this regulatory loop. Adrenal cortisol production could be influenced by IL-6 originating from perirenal adipose tissue surrounding the adrenal gland itself. In humans, IL-6 administration has been shown to induce a synchronized dose-dependent increase in resting metabolic rate and HPA activity, suggesting that hypothalamic CRH may mediate both of these functions (167). In contrast to stimulating ACTH, cortisol, GH, and prolactin release, IL-6 suppresses TSH secretion in a dose-dependent manner. This finding provides support to the participation of IL-6 and other inflammatory cytokines in generating the "euthyroid sick syndrome" in acute illness (92). The acute effects of IL-6 on GH, prolactin, and TSH release are also thought to be mediated via actions on hypothalamic control centers (108). Direct actions of IL-6 to modify anterior pituitary hormone release are plausible but unlikely, because they usually take more than 4-8 h to appear, and they have been documented to begin after 1 h of peaking between 3 and 4 h (167). Moreover, how circulating IL-6 reaches hypothalamic CRH and other regulatory neurons remains unclear, given the existence of the protective blood-brain barrier. There may be a special transport system for inflammatory cytokines, or they may directly activate the terminals of these neurons on the median eminence, which is outside the blood-brain barrier. Alternatively, IL-6 may cause endothelial and glial cells to secrete other mediators of inflammation, which reach the hypothalamic neurons in a cascade-like fashion (126).
Interestingly, no appreciable changes in luteinizing hormone (LH) and
follicle-stimulating hormone release in response to IL-6 administration
have been observed (167). This is in agreement with animal
studies (108) but contrasts with the inhibitory effects of
IL-1 and TNF- on the pulsatile release of LH (130).
The studies looking at the relation between plasma leptin and cortisol concentrations have yielded conflicting results (111). Diurnal variations of leptin and cortisol are inversely related, with leptin concentrations peaking during the nadir of cortisol secretion (95). Furthermore, physiological doses of leptin have been shown to inhibit ACTH-stimulated cortisol production in cultured cells (15). Leptin increases CRH expression in the paraventricular nucleus. Thus leptin and the HPA axis are reciprocally related, with interactions at several levels. Glucocorticoids have been suggested to exert a counterregulatory influence on leptin action, with the HPA axis activity possibly setting a level of target-organ sensitivity to leptin (190).
![]() |
CONCLUDING REMARKS |
---|
Adipocyte triglyceride stores are continously turning over at a
rate that is tightly controlled by hormones. The physiological, cellular, and molecular mechanisms regulating the primary function of
fat cells, to store excess ingested energy as triglycerides and to
release fatty acids to meet the energy needs of other tissues, have
been rapidly unfolding in the past decades. Novel metabolic functions
of adipose tissue, apart from its central role in triglyceride metabolism, have been uncovered. In addition to the classical actions
of insulin and counterregulatory hormones on adipocyte metabolism, fat
cells play an active role in modulating their own metabolism, and hence
their size, via autocrine and paracrine mechanisms. Newly discovered
roles include the production of the cytokines IL-6, TNF-, and
leptin, which play decisive roles in the development of obesity and
insulin resistance. The local production of angiotensinogen may play an
etiological role in the development of obesity-related hypertension.
Furthermore, synthesis of estrogens by adipose tissue may mediate
effects of obesity on the risk for osteoporosis and cancer. Thus the
enlargement of the adipose mass has pleiotropic effects on endocrine
and metabolic events at the whole body level that may contribute to the
pathogenesis of detrimental complications of obesity.
![]() |
FOOTNOTES |
---|
Address for reprint requests and other correspondence: G. Frühbeck, Dept. of Endocrinology, Clínica Universitaria de Navarra, 31008-Pamplona, Spain (E-mail: gfruhbeck{at}unav.es).
![]() |
REFERENCES |
---|
1.
Ahima, RS,
and
Flier JS.
Leptin.
Annu Rev Physiol
62:
413-437,
2000[ISI][Medline].
2.
Ailhaud, G,
and
Hauner H.
Development of white adipose tissue.
In: Handbook of Obesity (1st ed.), edited by Bray GA,
Bouchard C,
and James WPT. New York: Dekker, 1998, p. 359-378.
3.
Andersson, K,
Gaudiot N,
Ribière C,
Elizalde M,
Giudicelli Y,
and
Arner P.
A nitric oxide-mediated mechanism regulates lipolysis in human adipose tissue in vivo.
Br J Pharmacol
126:
1639-1645,
1999
4.
Armellini, F,
Zamboni M,
and
Bosello O.
Hormones and body composition in humans: clinical studies.
Int J Obes
24, Suppl2:
S18-S21,
2000[ISI].
5.
Arnalich, F,
López J,
Codoceo R,
Jiménez M,
Madero R,
and
Montiel C.
Relationship of plasma leptin to plasma cytokines and human survival in sepsis and septic shock.
J Infect Dis
180:
908-911,
1999[ISI][Medline].
6.
Baile, CA,
Della-Fera MA,
and
Martin RJ.
Regulation of metabolism and body fat mass by leptin.
Annu Rev Nutr
20:
105-127,
2000[ISI][Medline].
7.
Banks, AS,
Davis SM,
Bates SH,
and
Myers MG, Jr.
Activation of downstream signals by the long form of the leptin receptor.
J Biol Chem
275:
14563-14572,
2000
8.
Baumann, H,
Morella KK,
White DW,
Dembski M,
Bailon PS,
Kim H,
Lai CF,
and
Tartaglia LA.
The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors.
Proc Natl Acad Sci USA
93:
8374-8378,
1996
9.
Birgel, M,
Gottschling-Zeller H,
Röhrig K,
and
Hauner H.
Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes.
Arterioscler Thromb Vasc Biol
20:
1682-1687,
2000
10.
Bjørbæk, C,
El-Haschimi K,
Frantz JD,
and
Flier JS.
The role of SOCS-3 in leptin signaling and leptin resistance.
J Biol Chem
264:
30059-30065,
1999.
11.
Bjørbæk, C,
Uotani S,
da Silva B,
and
Flier JS.
Divergent signaling capacities of the long and short isoforms of the leptin receptor.
J Biol Chem
272:
32686-32695,
1997
12.
Björntorp, P.
The regulation of adipose tissue distribution in humans.
Int J Obes
20:
291-302,
1996[ISI][Medline].
13.
Boney, CM,
Gruppuso PA,
Faris RA,
and
Frackelton AR, Jr.
The critical role of Shc in insulin-like growth factor-I-mediated mitogenesis and differentiation in 3T3-L1 preadipocytes.
Mol Endocrinol
14:
805-813,
2000
14.
Boone, C,
Mourot J,
Grégoire F,
and
Remacle C.
The adipose conversion process: regulation by extracellular and intracellular factors.
Reprod Nutr Dev
40:
325-358,
2000[ISI][Medline].
15.
Bornstein, SR,
Uhlmann KI,
Haidan A,
Ehrhart-Bornstein M,
and
Scherbaum WA.
Evidence for a novel peripheral action of leptin as a metabolic signal to the adrenal gland: leptin inhibits cortisol release directly.
Diabetes
46:
1235-1238,
1997[Abstract].
16.
Casey, L,
Blak RA,
and
Bone RC.
Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis.
Ann Intern Med
119:
771-778,
1993
17.
Chehab, FF,
Lim ME,
and
Lu RH.
Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin.
Nature Genet
12:
318-320,
1996[ISI][Medline].
18.
Chen, NX,
Hausman GJ,
and
Wright JT.
Influence of thyroxine in vivo on preadipocyte development and insulin-like growth factor-I and IGF binding protein secretion in fetal stromal vascular cell cultures.
Obes Res
4:
357-366,
1996[Abstract].
19.
Choy, L,
Rosen B,
and
Spiegelman BM.
Adipsin and an endogenous pathway of complement from adipose cells.
J Biol Chem
267:
12736-12741,
1992
20.
Cioffi, JA,
Shafer AW,
Zupancic TJ,
Smith-Gbur J,
Mikhail A,
Platika D,
and
Snodgrass HR.
Novel B219/OB receptor isoforms: possible role of leptin in hematopoiesis and reproduction.
Nature Med
2:
585-589,
1996[ISI][Medline].
21.
Cook, KS,
Groves DL,
Min HY,
and
Spiegelman BM.
A developmentally regulated mRNA from 3T3 adipocytes encodes a novel serine protease homologue.
Proc Natl Acad Sci USA
82:
6480-6484,
1986[ISI].
22.
Cornelius, P,
MacDougald OA,
and
Lane MD.
Regulation of adipocyte development.
Annu Rev Nutr
14:
99-129,
1994[ISI][Medline].
23.
Couillard, C,
Mauriège P,
Imbeault P,
Prud'homme D,
Nadeau A,
Tremblay A,
Bouchard C,
and
Després JP.
Hyperleptinemia is more closely associated with adipose cell hypertrophy than with adipose tissue hyperplasia.
Int J Obes
24:
782-788,
2000[ISI].
24.
Darimont, C,
Vassaux G,
Ailhaud G,
and
Negrel R.
Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II.
Endocrinology
135:
2030-2036,
1994[Abstract].
25.
De Mitrio, V,
De Pergola G,
Vettor R,
Marino R,
Sciaraffia M,
Pagano C,
Scaraggi FA,
Di Lorenzo L,
and
Giorgino R.
Plasma plasminogen activator inhibitor-1 is associated with plasma leptin irrespective of body mass index, body fat mass, and plasma insulin and metabolic parameters in premenopausal women.
Metabolism
48:
960-964,
1999[ISI][Medline].
26.
De Vos, P,
Lefebvre AM,
Miller SG,
Guerre-Millo M,
Wong K,
Saladin R,
Hamann LG,
Staels B,
Briggs MR,
and
Auwerx J.
Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor .
J Clin Invest
98:
1004-1009,
1996
27.
Dieudonne, MN,
Pecquery R,
Leneveu MC,
and
Giudicelli Y.
Opposite effects of androgens and estrogens on adipogenesis in rat preadipocytes: evidence for sex- and site-related specificities and possible involvement of insulin-like growth factor 1 receptor and peroxisome proliferator-activated receptor gamma2.
Endocrinology
141:
649-656,
2000
28.
Dong, ZM,
Gutierrez-Ramos JC,
Coxon A,
Mayadas TN,
and
Wagner DD.
A new class of obesity genes encodes leukocyte adhesion receptors.
Proc Natl Acad Sci USA
94:
7526-7530,
1997
29.
Drucker, DJ.
Glucagon-like peptides.
Diabetes
47:
159-169,
1998[Abstract].
30.
Ducy, P,
Amling M,
Takeda S,
Priemel M,
Schilling AF,
Beil FT,
Shen J,
Vinson C,
Rueger JM,
and
Karsenty G.
Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass.
Cell
100:
195-207,
2000.
31.
Dyer, CJ,
Simmons JM,
Matteri RL,
and
Keisler DH.
Effects of an intravenous injection of NPY on leptin and NPY-Y1 receptor mRNA expression in ovine adipose tissue.
Domest Anim Endocrinol
14:
325-333,
1997[ISI][Medline].
32.
Eckel, RH.
Insulin resistance: an adaptation for weight maintenance.
Lancet
340:
1452-1453,
1992[ISI][Medline].
33.
Eigler, A,
Sinha B,
Hartmann G,
and
Enders S.
Taming TNF: strategies to restrain this proinflammatory cytokine.
Immunol Today
18:
487-492,
1997[ISI][Medline].
34.
Endo, T,
Ohta K,
Haraguchi K,
and
Onaya T.
Cloning and functional expression of a thyrotropin receptor cDNA from rat fat cells.
J Biol Chem
270:
10833-10837,
1995
35.
Feinstein, R,
Kanety H,
Papa MZ,
Lunenfeld B,
and
Karasik A.
Tumor necrosis factor alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates.
J Biol Chem
268:
26055-26058,
1993
36.
Finck, BN,
and
Johnson RW.
Tumor necrosis factor (TNF)- induces leptin production through the p55 TNF receptor.
Am J Physiol Regulatory Integrative Comp Physiol
278:
R537-R543,
2000
37.
Flier, JS.
The adipocyte: storage depot or node on the energy information superhighway?
Cell
80:
15-18,
1995[ISI][Medline].
38.
Frayn, KN,
Humphreys SM,
and
Coppack SW.
Fuel selection in white adipose tissue.
Proc Nutr Soc
54:
177-189,
1995[ISI][Medline].
39.
Frayn, KN,
Shadid S,
Hamlani R,
Humphreys SM,
Clark ML,
Fielding BA,
Boland O,
and
Coppack SW.
Regulation of fatty acid movement in human adipose tissue in the postabsorptive-to-postprandial transition.
Am J Physiol Endocrinol Metab
266:
E308-E317,
1994
40.
Fried, SK,
Bunkin DA,
and
Greenberg AS.
Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid.
J Clin Endocrinol Metab
83:
847-850,
1998
41.
Fried, SK,
and
Russell CD.
Diverse roles of adipose tissue in the regulation of systemic metabolism and energy balance.
In: Handbook of Obesity (1st ed.), edited by Bray GA,
Bouchard C,
and James WPT. New York: Dekker, 1998, p. 397-413.
42.
Frühbeck, G.
Pivotal role of nitric oxide in the control of blood pressure following leptin administration.
Diabetes
48:
903-908,
1999[Abstract].
43.
Frühbeck, G,
Aguado M,
and
Martínez JA.
In vitro lipolytic effect of leptin on mouse adipocytes: evidence for a possible autocrine/paracrine role of leptin.
Biochem Biophys Res Commun
240:
590-594,
1997[ISI][Medline].
44.
Frühbeck, G,
Jebb SA,
and
Prentice AM.
Leptin: physiology and pathophysiology.
Clin Physiol
18:
399-419,
1998[ISI][Medline].
45.
Frystyk, J,
Vestbo E,
Skjaerbaek C,
Mogensen CE,
and
Orskov H.
Free insulin-like growth factors in human obesity.
Metabolism
44:
37-44,
1995[ISI][Medline].
46.
Gainsford, T,
Willson TA,
Metcalf D,
Handman E,
McFarlane C,
Ng A,
Nicola NA,
Alexander WS,
and
Hilton DJ.
Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells.
Proc Natl Acad Sci USA
93:
14564-14568,
1996
47.
Gale, SK,
Van Itallie TB,
and
Faust IM.
Effects of palatable diets on body weight and adipose tissue cellularity in the adult obese female Zucker rat (fa/fa).
Metabolism
30:
105-110,
1981[ISI][Medline].
48.
Gaudiot, N,
Jaubert AM,
Charbonnier E,
Sabourault D,
Lacasa D,
Giudicelli Y,
and
Ribière C.
Modulation of white adipose tissue lipolysis by nitric oxide.
J Biol Chem
273:
13475-13481,
1998
49.
Germinario, R,
Sniderman AD,
Manuel S,
Lefebvre SP,
Baldo A,
and
Cianflore K.
Coordinating regulation of triacylglycerol synthesis and glucose transport by acylation stimulating protein.
Metabolism
42:
574-580,
1993[ISI][Medline].
50.
Gottschling-Zeller, H,
Birgel M,
Scriba D,
Blum WF,
and
Hauner H.
Depot-specific release of leptin from subcutaneous and omental adipocytes in suspension culture: effect of tumor necrosis factor- and transforming growth factor-
1.
Eur J Endocrinol
141:
436-442,
1999[ISI][Medline].
51.
Greenberg, AS,
Nordan RP,
McIntosh J,
Calvo JP,
Scow RO,
and
Jablons D.
Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia.
Cancer Res
52:
4113-4116,
1992[Abstract].
52.
Grell, M.
Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF.
J Inflamm
47:
8-17,
1995-96[ISI][Medline].
53.
Grunfeld, C,
and
Feingold KR.
The metabolic effects of tumor necrosis factor and other cytokines.
Biotherapy
3:
143-158,
1991[ISI][Medline].
54.
Grunfeld, C,
Zhao C,
Fuller J,
Pollack A,
Moser A,
Friedman J,
and
Feingold KR.
Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters.
J Clin Invest
97:
2152-2157,
1996
55.
Hauner, H,
Bender M,
Haastert B,
and
Hube F.
Plasma concentrations of TNF- and its soluble receptors in obese subjects.
Int J Obes
22:
1239-1243,
1998[ISI].
56.
Hauner, H,
Petruschke T,
Russ M,
Röhrig K,
and
Eckel J.
Effects of tumour necrosis factor alpha (TNF) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture.
Diabetologia
38:
764-771,
1995[ISI][Medline].
57.
Hauner, H,
Röhrig K,
and
Petruschke T.
Effects of epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) on human adipocyte development and function.
Eur J Clin Invest
25:
90-96,
1995[ISI][Medline].
58.
Heaney, ML,
and
Golde DW.
Soluble hormone receptors.
Blood
82:
1945-1948,
1993[ISI][Medline].
59.
Heid, HW,
Moll R,
Schwetlick I,
Rackwitz HR,
and
Keenan TW.
Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases.
Cell Tissue Res
294:
309-321,
1998[ISI][Medline].
60.
Hirsch, J,
and
Batchelor B.
Adipose tissue cellularity in human obesity.
Clin Endocrinol Metab
5:
299-311,
1976[ISI][Medline].
61.
Hotamisligil, GS,
Arner P,
Atkinson RL,
and
Spiegelman BM.
Differential regulation of the p80 of tumor necrosis factor receptor in human obesity and insulin resistance.
Diabetes
46:
451-455,
1997[Abstract].
62.
Hotamisligil, GS,
Arner P,
Caro JF,
Atkinson RL,
and
Spiegelman BM.
Increased adipose tissue expression of tumor necrosis factor- in human obesity and insulin resistance.
J Clin Invest
95:
2409-2415,
1995[ISI][Medline].
63.
Hotamisligil, GS,
Johnson RS,
Distel RJ,
Ellis R,
Papaioannou VE,
and
Spiegelman BM.
Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein.
Science
274:
1377-1379,
1996
64.
Hotamisligil, GS,
Peraldi P,
Budavari A,
Ellis R,
White MF,
and
Spiegelman BM.
IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-- and obesity-induced insulin resistance.
Science
271:
665-668,
1996[Abstract].
65.
Hotamisligil, GS,
Shargill NS,
and
Spiegelman BM.
Adipose expression of tumor necrosis factor-: direct role in obesity-linked insulin resistance.
Science
259:
87-91,
1993[ISI][Medline].
66.
Hotta, K,
Funahashi T,
Arita Y,
Takahashi M,
Mastsuda M,
Okamoto Y,
Iwahashi H,
Kuriyama H,
Maeda K,
Nishida M,
Kihara S,
Sakai N,
Nakajima T,
Yamashita S,
Hanafusa T,
and
Matsuzawa Y.
Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.
Arterioscler Thromb Vasc Biol
20:
1595-1599,
2000
67.
Hu, E,
Liang P,
and
Spiegelman BM.
AdipoQ is a novel adipose-specific gene dysregulated in obesity.
J Biol Chem
271:
10697-10703,
1996
68.
Hube, F,
Birgel M,
Lee YM,
and
Hauner H.
Expression pattern of tumour necrosis factor receptors in subcutaneous and omental human adipose tissue: role of obesity and non-insulin-dependent diabetes mellitus.
Eur J Clin Invest
29:
672-678,
1999[ISI][Medline].
69.
Hube, F,
and
Hauner H.
The role of TNF- in human adipose tissue: prevention of weight gain at the expense of insulin resistance?
Horm Metab Res
31:
626-631,
1999[ISI][Medline].
70.
Hube, F,
Lee YM,
Röhrig K,
and
Hauner H.
The phosphodiesterase inhibitor IBMX suppresses TNF- expression in human adipocyte precursor cells: a possible explanation for its adipogenic effect.
Horm Metab Res
31:
359-362,
1999[ISI][Medline].
71.
Ihle, JN,
and
Kerr IM.
Jaks and Stats in signaling by the cytokine receptor superfamily.
Trends Genet
11:
69-74,
1995[ISI][Medline].
72.
Imura, H,
Fukara J,
and
Mori T.
Cytokines and endocrine function: an interaction between the immune and neuroendocrine systems.
Clin Endocrinol
35:
107-115,
1997.
73.
Iwanij, V,
Amos TM,
and
Billington CJ.
Identification and characterization of the glucagon receptor from adipose tissue.
Mol Cell Endocrinol
101:
257-261,
1994[ISI][Medline].
74.
Janik, JE,
Curti BD,
Considine RV,
Rager HC,
Powers GC,
Alvord WG,
Smith JW, II,
Gause BL,
and
Kopp WC.
Interleukin 1 increases serum leptin concentrations in humans.
J Clin Endocrinol Metab
82:
3084-3086,
1997
75.
Jensen, MD.
Lipolysis: contribution from regional fat.
Annu Rev Nutr
17:
127-139,
1997[ISI][Medline].
76.
Jones, BH,
Standridge MK,
Taylor JW,
and
Moustaid N.
Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control.
Am J Physiol Regulatory Integrative Comp Physiol
273:
R236-R242,
1997
77.
Jones, SA,
Horiuchi S,
Topley N,
Yamamoto N,
and
Fuller GM.
The soluble interleukin 6 receptor: mechanisms of production and implications in disease.
FASEB J
15:
43-58,
2001
78.
Juhan-Vague, I,
and
Alessi MC.
PAI-1, obesity, insulin resistance and risk of cardiovascular events.
Thromb Haemostasis
78:
656-660,
1997[ISI][Medline].
79.
Kamei, Y,
Kawada T,
Kazuki R,
Ono T,
Kato S,
and
Sugimoto E.
Vitamin D receptor gene expression is up-regulated by 1,25-dihydroxyvitamin D3 in 3T3-L1 preadipocytes.
Biochem Biophys Res Commun
193:
948-955,
1993[ISI][Medline].
80.
Kanety, H,
Hemi R,
Papa MZ,
and
Karasik A.
Sphingomyelinase and ceramide suppress insulin-induced tyrosine phosphorylation of the insulin receptor substrate-1.
J Biol Chem
271:
9895-9897,
1996
81.
Kern, PA,
Saghizadeh M,
Ong JM,
Bosch RJ,
Deem R,
and
Simsolo RB.
The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase.
J Clin Invest
95:
2111-2119,
1995[ISI][Medline].
82.
Kieffer, TJ,
and
Habener JF.
The adipoinsular axis: effects of leptin on pancreatic -cells.
Am J Physiol Endocrinol Metab
278:
E1-E14,
2000
83.
Kim, JK,
Michael MD,
Previs SF,
Peroni OD,
Mauvais-Jarvis F,
Neschen S,
Kahn BB,
Kahn CR,
and
Shulman GI.
Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle.
J Clin Invest
105:
1791-1797,
2000
84.
Kim, YB,
Uotani S,
Pierroz DD,
Flier JS,
and
Kahn BB.
In vivo administration of leptin activates signal transduction directly in insulin-sensitive tissues: overlapping but distinct pathways from insulin.
Endocrinology
141:
2328-2339,
2000
85.
Kirchgessner, TG,
Uysal KT,
Wiesbrock SM,
Marino MW,
and
Hotamisligil GS.
Tumor necrosis factor contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes.
J Clin Invest
100:
2777-2782,
1997
86.
Klebig, ML,
Wilkinson JE,
Geisler JG,
and
Woychik RP.
Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes and yellow fur.
Proc Natl Acad Sci USA
92:
4728-4732,
1996[Abstract].
87.
Kopelman, PG.
Effects of obesity on fat topography: metabolic and endocrine determinants.
In: Clinical Obesity (1st ed.), edited by Kopelman PG,
and Stock MJ.. Oxford, UK: Blackwell Science, 1998, p. 158-175.
88.
Kraemer, FB,
Laane C,
Park B,
and
Sztalryd C.
Low-density lipoprotein receptors in rat adipocytes: regulation with fasting.
Am J Physiol Endocrinol Metab
266:
E26-E32,
1994
89.
Kras, KM,
Hausman DB,
and
Martin RJ.
Tumor necrosis factor- stimulates cell proliferation in adipose tissue-derived stromal-vascular cell culture: promotion of adipose tissue expansion by paracrine growth factors.
Obes Res
8:
186-193,
2000
90.
Kroder, G,
Bossenmaier B,
Kellerer M,
Capp E,
Stoyanov B,
Mühlhöfer A,
Berti L,
Horikoshi H,
Ullrich A,
and
Häring H.
Tumor necrosis factor-- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling.
J Clin Invest
97:
1471-1477,
1996
91.
Lafontan, M,
and
Berlan M.
Fat cell adrenergic receptors and the control of white and brown fat cell function.
J Lipid Res
34:
1057-1091,
1993[Abstract].
92.
Lechan, RM.
Update on thyroid releasing hormone.
Thyroid Today
16:
1-11,
1993.
93.
Lee, GH,
Proenca R,
Montez JM,
Carroll K,
Darvishzadeh JG,
Lee JI,
and
Friedman JM.
Abnormal splicing of the leptin receptor in diabetic mice.
Nature
379:
632-635,
1996[ISI][Medline].
94.
Li, C,
and
Friedman JM.
Leptin receptor activation of SH2 domain containing protein tyrosine phosphatase 2 modulates Ob receptor signal transduction.
Proc Natl Acad Sci USA
96:
9677-9682,
1999
95.
Licinio, J,
Mantzoros C,
Negrao AB,
Cizza G,
Wong ML,
Bongiono PB,
Chrousos GP,
Karp B,
Allen C,
Flier JS,
and
Gold PW.
Human leptin levels are pulsatile and inversely related to pituitary-adrenal function.
Nature Med
3:
575-579,
1997[ISI][Medline].
96.
Liu, LS,
Spelleken M,
Röhrig K,
Hauner H,
and
Eckel J.
Tumor necrosis factor- acutely inhibits insulin signaling in human adipocytes. Implication of the p80 tumor necrosis factor receptor.
Diabetes
47:
515-522,
1998[Abstract].
97.
Löllmann, B,
Grüninger S,
Stricker-Krongrad A,
and
Chiesi M.
Detection and quantification of the leptin receptor splice variants Ob-Ra, b, and e in different mouse tissues.
Biochem Biophys Res Commun
238:
648-652,
1997[ISI][Medline].
98.
Lord, GM,
Matarese G,
Howard JK,
Baker RJ,
Bloom SR,
and
Lechler RI.
Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression.
Nature
394:
897-901,
1998[ISI][Medline].
99.
Lowell, BB.
PPAR: an essential regulator of adipogenesis and modulator of fat cell function.
Cell
99:
239-242,
1999[ISI][Medline].
100.
Machinal, F,
Dieudonne MN,
Leneveu MC,
Pecquery R,
and
Giudicelli Y.
In vivo and in vitro ob gene expression and leptin secretion in rat adipocytes: evidence for a regional specific regulation by sex steroid hormones.
Endocrinology
140:
1567-1574,
1999
101.
Madej, T,
Boguski MS,
and
Bryant SH.
Threading analysis suggests that the obese gene product may be a helical cytokine.
FEBS Lett
373:
13-18,
1995[ISI][Medline].
102.
Manne, J,
Argeson AC,
and
Siracusa LD.
Mechanisms for the pleiotropic effects of the agouti gene.
Proc Natl Acad Sci USA
92:
4721-4724,
1995
103.
Mantzoros, CS.
The role of leptin in human obesity and disease: a review of current evidence.
Ann Intern Med
130:
671-680,
1999
104.
Mantzoros, CS,
Moschos S,
Avramopoulos I,
Kaklamani V,
Liolios A,
Doulgerakis DE,
Griveas I,
Katsilambros N,
and
Flier JS.
Leptin concentrations in relation to body mass index and the tumor necrosis factor- system in humans.
J Clin Endocrinol Metab
82:
3408-3413,
1997
105.
Marques, BG,
Hausman DB,
Latimer AM,
Kras KM,
Grossman BM,
and
Martin RJ.
Insulin-like growth factor I mediates high-fat diet-induced adipogenesis in Osborne-Mendel rats.
Am J Physiol Regulatory Integrative Comp Physiol
278:
R654-R662,
2000
106.
Maslowska, M,
Scantlebury T,
Germinario R,
and
Cianflore K.
Acute in vitro production of acylation stimulating protein in differentiated human adipocytes.
J Lipid Res
38:
1-11,
1997[Abstract].
107.
Mavri, A,
Stegnar M,
Krebs M,
Sentocnik JT,
Geiger M,
and
Binder BR.
Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women.
Arterioscler Thromb Vasc Biol
19:
1582-1587,
1999
108.
McCann, SM,
Karanth S,
Kamat A,
Les Dees W,
Lyson K,
Gimeno M,
and
Rettori V.
Induction by cytokines of the pattern of pituitary hormone secretion in infection.
Neuroimmunomodulation
1:
2-13,
1994[Medline].
109.
Mohamed-Ali, V,
Goodrick S,
Bulmer K,
Holly JM,
Yudkin JS,
and
Coppack SW.
Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo.
Am J Physiol Endocrinol Metab
277:
E971-E975,
1999
110.
Mohamed-Ali, V,
Goodrick S,
Rawesh A,
Katz DR,
Miles JM,
Yudkin JS,
Klein S,
and
Coppack SW.
Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-, in vivo.
J Clin Endocrinol Metab
82:
4196-4200,
1997
111.
Mohamed-Ali, V,
Pinkney JH,
and
Coppack SW.
Adipose tissue as an endocrine and paracrine organ.
Int J Obes
22:
1145-1158,
1998[ISI][Medline].
112.
Montague, CT,
Prins JB,
Sanders L,
Digby JE,
and
O'Rahilly S.
Depot- and sex-specific differences in human leptin mRNA expression. Implications for the control of regional fat distribution.
Diabetes
46:
342-347,
1997[Abstract].
113.
Morin, CL,
Eckel RH,
Marcel T,
and
Pagliassotti MJ.
High fat diets elevate tissue-derived tumor necrosis factor- activity.
Endocrinology
138:
4665-4671,
1997
114.
Nakashima, K,
Narazaki M,
and
Taga T.
Overlapping and distinct signals through leptin receptor (OB-R) and a closely related cytokine signal transducer, gp130.
FEBS Lett
401:
49-52,
1997[ISI][Medline].
115.
Navre, M,
and
Ringold GM.
Differential effects of fibroblast growth factor and tumor promoters on the initiation and maintenance of adipocyte differentiation.
J Cell Biol
109:
1857-1863,
1989[Abstract].
116.
Nonogaki, K,
Fuller GM,
Fuentes NL,
Moser AH,
Staprans I,
and
Grunfeld C.
Interleukin-6 stimulates hepatic triglyceride secretion in rats.
Endocrinology
136:
2143-2149,
1995[Abstract].
117.
O'Brien, SN,
Welter BH,
Mantzke KA,
and
Price TM.
Identification of progesterone receptor in human subcutaneous adipose tissue.
J Clin Endocrinol Metab
83:
509-513,
1998
118.
Ofei, F,
Hurel S,
Newkirk J,
Sopwith M,
and
Taylor R.
Effects of an engineered human anti-TNF- antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM.
Diabetes
45:
881-885,
1996[Abstract].
119.
Papanicolaou, DA,
Petrides JS,
Tsigos C,
Bina S,
Kalogeras KT,
Wilder R,
Gold PW,
Deuster PA,
and
Chrousos GP.
Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines.
Am J Physiol Endocrinol Metab
271:
E601-E605,
1996.
120.
Paz, K,
Hemi R,
LeRoith D,
Karasik A,
Elhanany E,
and
Kanety H.
A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced thyrosine phosphorylation.
J Biol Chem
272:
29911-29918,
1997
121.
Peraldi, P,
Hotamisligil GS,
Buurman WA,
White MF,
and
Spiegelman BM.
Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphyngomyelinase.
J Biol Chem
271:
13018-13022,
1996
122.
Petruschke, T,
and
Hauner H.
Tumor necrosis factor-alpha prevents the differentiation of human adipocyte precursor cells and causes delipidation of newly developed fat cells.
J Clin Endocrinol Metab
76:
742-747,
1993[Abstract].
123.
Pfeiffer, A,
Janot J,
Möhlig M,
Ristow M,
Rochlitz H,
Busch K,
Schatz H,
and
Schifferdecker E.
Circulating tumor necrosis factor is elevated in male but not in female patients with type II diabetes mellitus.
Horm Metab Res
29:
111-114,
1997[ISI][Medline].
124.
Pickup, JC,
Chusney GD,
Thomas SM,
and
Burt D.
Plasma interleukin-6, tumour necrosis factor and blood cytokine production in type 2 diabetes.
Life Sci
67:
291-300,
2000[ISI][Medline].
125.
Pinkney, JH,
Coppack SW,
and
Mohamed-Ali V.
Effect of isoprenaline on plasma leptin and lipolysis in humans.
Clin Endocrinol
48:
407-411,
1998[ISI][Medline].
126.
Pober, JS,
and
Cotran RS.
Cytokines and endothelial cell biology.
Physiol Rev
70:
427-451,
1990
127.
Potts, JL,
Coppack SW,
Fisher RM,
Humphreys SM,
Gibbons GF,
and
Frayn KN.
Impaired postprandial clearance of triacylglycerol-rich lipoproteins in adipose tissue in obese subjects.
Am J Physiol Endocrinol Metab
268:
E588-E594,
1995
128.
Prins, JB,
Niesler CU,
Winterford CM,
Bright NA,
Siddle K,
O'Rahilly S,
Walker N,
and
Cameron DP.
Tumor necrosis factor- induces apoptosis of human adipose cells.
Diabetes
46:
1939-1944,
1997[Abstract].
129.
Ramsay, TG.
Fat cells.
Endocrinol Metab Clin North Am
25:
847-879,
1996[ISI][Medline].
130.
Rettori, V,
Gimeno MF,
Gonzalez MC,
and
McCann SM.
Interleukin 1 inhibits prostaglandin E2 to suppress pulsatile release of luteinizing hormone but not follicle stimulating hormone.
Proc Natl Acad Sci USA
88:
2863-2867,
1991.
131.
Ribière, C,
Jaubert AM,
Gaudiot N,
Sabourault D,
Marcus ML,
Boucher JL,
Denis-Henriot D,
and
Giudicelli Y.
White adipose tissue nitric oxide synthase: a potential source for NO production.
Biochem Biophys Res Commun
222:
706-712,
1996[ISI][Medline].
132.
Rigden, DJ,
Jellyman AE,
Frayn KN,
and
Coppack SW.
Human adipose tissue glycogen levels and responses to carbohydrate feeding.
Eur J Clin Nutr
44:
689-692,
1990[ISI][Medline].
133.
Saito, T,
Yasukawa K,
Suzuki H,
Futatsugi K,
Fukunaga T,
Yokomizo C,
Kishihara Y,
Fukui H,
Ohsugi Y,
Yawata H,
Kobayashi I,
Hirano T,
Taga T,
and
Kishimoto T.
Preparation of soluble murine IL-6 receptor and anti-murine IL-6 receptor antibodies.
J Immunol
147:
168-173,
1991
134.
Sakaue, S,
Nishihira J,
Hirokawa J,
Yoshimura H,
Honda T,
Aoki K,
Tagami S,
and
Kawakami Y.
Regulation of macrophage migration inhibitory factor (MIF) expression by glucose and insulin in adipocytes in vitro.
Mol Med
5:
361-371,
1999[ISI][Medline].
135.
Salter, AM,
Fong BS,
Jimenez J,
Rotstein L,
and
Angel A.
Regional variation in high-density lipoprotein binding to human adipocyte plasma membranes of massively obese subjects.
Eur J Clin Invest
17:
16-22,
1987[ISI][Medline].
136.
Samad, F,
and
Loskuttof DJ.
Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice.
Mol Med
2:
568-582,
1996[ISI][Medline].
137.
Samad, F,
Yamamoto K,
Pandey M,
and
Loskuttof DJ.
Elevated expression of transforming growth factor- in adipose tissue from obese mice.
Mol Med
3:
37-48,
1997[ISI][Medline].
138.
Sarraf, P,
Frederich RC,
Turner EM,
Ma G,
Jaskowiak NT,
Rivet DJ,
Flier JS,
Lowell BB,
Fraker DL,
and
Alexander HR.
Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia.
J Exp Med
185:
171-175,
1997
139.
Sarzani, R,
Paci VM,
Zingaretti CM,
Pierleoni C,
Cinti S,
Cola G,
Rappelli A,
and
Dessi-Fulgheri P.
Fasting inhibits natriuretic peptides clearance receptor expression in rat adipose tissue.
J Hypertens
13:
1241-1246,
1995[ISI][Medline].
140.
Scherer, PE,
Williams S,
Fogliano M,
Baldini G,
and
Lodish HF.
A novel serum protein similar to C1q, produced exclusively in adipocytes.
J Biol Chem
270:
26746-26749,
1996
141.
Schmidt, W,
Poll-Jordan G,
and
Loffler G.
Adipose conversion of 3T3-L1 cells in a serum-free culture system depends on epidermal growth factor, insulin-like growth factor I, corticosterone, and cyclic AMP.
J Biol Chem
265:
15489-15495,
1990
142.
Schreyer, SA,
Streamson CC,
and
LeBoeuf RC.
Obesity and diabetes in TNF- receptor-deficient mice.
J Clin Invest
102:
402-411,
1998
143.
Serrero, G,
and
Lepak N.
Endocrine and paracrine negative regulators of adipose differentiation.
Int J Obes
20, Suppl3:
S58-S64,
1996[ISI].
144.
Shaughnessy, S,
Smith ER,
Kodukula S,
Storch J,
and
Fried SK.
Adipocyte metabolism in adipocyte fatty acid binding protein knockout (aP2-/-) mice after short-term high-fat feeding.
Diabetes
49:
904-911,
2000[Abstract].
145.
Shimabukuro, M,
Koyama K,
Chen G,
Wang MY,
Trieu F,
Lee Y,
Newgard CB,
and
Unger RH.
Direct antidiabetic effect of leptin through triglyceride depletion of tissues.
Proc Natl Acad Sci USA
94:
4637-4641,
1997
146.
Shimomura, I,
Funahashi T,
Takahashi M,
Maeda K,
Kotani K,
Nakamura T,
Yamashita S,
Miura M,
Fukuda Y,
Takemura K,
Tokunaga K,
and
Matsuzawa Y.
Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity.
Nat Med
2:
800-803,
1996[ISI][Medline].
147.
Sierra-Honigmann, MR,
Nath AK,
Murakami C,
García-Cardeña G,
Papapetropoulos A,
Sessa WC,
Madge LA,
Schechner JS,
Schwabb MB,
Polverini PJ,
and
Flores-Riveros JR.
Biological action of leptin as an angiogenic factor.
Science
281:
1683-1686,
1998
148.
Sniderman, AD,
and
Cianflore K.
The adipsin-ASP pathway and regulation of adipocyte function.
Ann Intern Med
26:
389-393,
1994.
149.
Sniderman, AD,
Cianflore K,
and
Eckel RH.
Levels of acylation stimulating protein in obese women before and after moderate weight loss.
Int J Obes
15:
333-336,
1991[ISI][Medline].
150.
Soderberg, S,
Olsson T,
Eliasson M,
Johnson O,
and
Ahren B.
Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women.
J Intern Med
245:
533-543,
1999[ISI][Medline].
151.
Spiegelman, BM,
and
Flier JS.
Adipogenesis and obesity: rounding out the big picture.
Cell
87:
377-389,
1996[ISI][Medline].
152.
Spiegelman, BM,
and
Green H.
Control of specific protein biosynthesis during the adipose conversion of 3T3 cells.
J Biol Chem
255:
8811-8818,
1980
153.
Spiegelman, BM,
Choy L,
Hotamisligil GS,
Graves RA,
and
Tontonoz P.
Regulation of adipocyte gene expression in differentiation and syndromes of obesity/diabetes.
J Biol Chem
268:
6823-6826,
1993
154.
Sporn, MB,
Roberts AB,
Wakefield LM,
and
de Crombrugghe B.
Some recent advances in the chemistry and biology of transforming growth factor-.
J Cell Biol
105:
1039-1045,
1987[ISI][Medline].
155.
Stephens, JM,
Lee J,
and
Pilch PF.
Tumor necrosis factor--induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction.
J Biol Chem
272:
971-976,
1997
156.
Stephens, JM,
and
Pekala PH.
Transcriptional repression of Glut-4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor alpha.
J Biol Chem
266:
21839-21845,
1992
157.
Stoyan, T,
Michaelis U,
Schooltink H,
Van-Dam M,
Rudolph R,
Heinrich PC,
and
Rose-John S.
Recombinant soluble human interleukin-6 receptor. Expression in Escherichia coli, renaturation and purification.
Eur J Biochem
216:
239-245,
1993[Abstract].
158.
Strassmann, G,
Fong M,
Kenney JS,
and
Jacob CO.
Evidence for the involvement of interleukin 6 in experimental cancer cachexia.
J Clin Invest
89:
1681-1684,
1992[ISI][Medline].
159.
Szanto, I,
and
Kahn CR.
Selective interaction between leptin and insulin signaling pathways in a hepatic cell line.
Proc Natl Acad Sci USA
97:
2355-2360,
2000
160.
Taga, T,
Hibi M,
Hirata Y,
Yamasaki K,
Yasukawa K,
Matsuda T,
Hirano T,
and
Kishimoto T.
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130.
Cell
58:
573-581,
1989[ISI][Medline].
161.
Tartaglia, LA.
The leptin receptor.
J Biol Chem
272:
6093-6096,
1997
162.
Taylor, JE,
Scott CD,
and
Baxter RC.
Comparison of receptors for insulin-like growth factor II from various rat tissues.
J Endocrinol
115:
35-41,
1987[Abstract].
163.
Tiebel, O,
Oka K,
Robinson K,
Sullivan M,
Martinez J,
Nakamuta M,
Ishimura-Oka K,
and
Chan L.
Mouse very low-density lipoprotein receptor (VLDLR): gene structure, tissue-specific expression and dietary and developmental regulation.
Atherosclerosis
145:
239-251,
1999[ISI][Medline].
164.
Torres-Márquez, ME,
Romero-Avila MT,
González-Espinosa C,
and
Garcia-Sainz J.
A characterization of rat white fat cell 1B-adrenoceptors.
Mol Pharmacol
42:
403-406,
1992[Abstract].
165.
Torti, FM,
Dieckmann B,
Beutler B,
Cerami A,
and
Ringold GM.
A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia.
Science
229:
867-869,
1985[ISI][Medline].
166.
Trayhurn, P.
New insights into the development of obesity: obese genes and the leptin system.
Proc Nutr Soc
55:
783-791,
1996[ISI][Medline].
167.
Tsigos, C,
Papanicolaou DA,
Mitsiadis CS,
Kyrou I,
and
Chrousos GP.
Dose effects of recombinant interleukin-6 on pituitary hormone secretion and energy expenditure.
Neuroendocrinology
66:
54-62,
1997[ISI][Medline].
168.
Uysal, KT,
Wiesbrock SM,
and
Hotamisligil GS.
Functional analysis of tumor necrosis factor (TNF) receptors in TNF--mediated insulin resistance in genetic obesity.
Endocrinology
139:
4832-4838,
1998
169.
Uysal, KT,
Wiesbrock SM,
Marino MW,
and
Hotamisligil GS.
Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function.
Nature
389:
610-614,
1997[ISI][Medline].
170.
Vague, P,
Juhan-Vague I,
Aillaud MF,
Badier C,
Viard R,
Alessi MC,
and
Collen D.
Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects.
Metabolism
35:
250-253,
1986[ISI][Medline].
171.
Van Harmelen, V,
Elizalde M,
Ariapart P,
Bergstedt-Lindqvist S,
Reynisdottir S,
Hoffstedt J,
Lundkvist I,
Bringman S,
and
Arner P.
The association of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity.
Int J Obes
24:
673-678,
2000[ISI].
172.
Van Snick, J.
Interleukin-6: an overview.
Annu Rev Immunol
8:
253-278,
1996[ISI][Medline].
173.
Van-Zee, KJ,
Kohno T,
Fischer E,
Rock CS,
Moldawer LL,
and
Lowry SF.
Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.
Proc Natl Acad Sci USA
89:
4845-4849,
1992[Abstract].
174.
Vassaux, G,
Gaillard D,
Mari B,
Ailhaud G,
and
Negrel R.
Differential expression of adenosine A1 and A2 receptors in preadipocytes and adipocytes.
Biochem Biophys Res Commun
193:
1123-1130,
1993[ISI][Medline].
175.
Vgontzas, AN,
Papanicolaou DA,
Bixler EO,
Kales A,
Tyson K,
and
Chrousos GP.
Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity.
J Clin Endocrinol Metab
82:
1313-1316,
1997
176.
Vikman, K,
Carlsson B,
Billig H,
and
Eden S.
Expression and regulation of growth hormone (GH) receptor messenger ribonucleic acid (mRNA) in rat adipose tissue, adipocytes, and adipocyte precursor cells: GH regulation of GH receptor mRNA.
Endocrinology
129:
1155-1161,
1991[Abstract].
177.
Villarroya, F,
Giralt M,
and
Iglesias R.
Retinoids and adipose tissues: metabolism, cell differentiation and gene expression.
Int J Obes
23:
1-6,
1999[ISI].
178.
Wabitsch, M,
Hauner H,
Heinze E,
and
Teller WM.
The role of growth hormone/insulin growth factors in adipocyte differentiation.
Metabolism
44:
45-49,
1995[ISI][Medline].
179.
Wang, J,
Liu R,
Hawkins M,
Barzilai N,
and
Rossetti L.
A nutrient-sensing pathway regulates leptin gene expression in muscle and fat.
Nature
393:
684-688,
1998[ISI][Medline].
180.
Wang, MY,
Lee Y,
and
Unger RH.
Novel form of lipolysis induced by leptin.
J Biol Chem
274:
17541-17544,
1998
181.
Wang, ZW,
Zhou YT,
Lee Y,
Higa M,
Kalra SP,
and
Unger RH.
Hyperleptinemia depletes fat from denervated fat tissue.
Biochem Biophys Res Commun
260:
653-657,
1999[ISI][Medline].
182.
Wiman, B,
Chmielewska J,
and
Ranby M.
Inactivation of tissue plasminogen activator in plasma: demonstration of a complex with a new rapid inhibitor.
J Biol Chem
259:
3644-3647,
1984
183.
Wootan, MG,
Bernlohr DA,
and
Storch J.
Mechanism of fluorescent fatty acid transfer from adipocyte fatty acid binding protein to membranes.
Biochemistry
32:
8622-8627,
1993[ISI][Medline].
184.
Xing, H,
Northrop JP,
Grove JR,
Kilpatrick KE,
Su JL,
and
Ringold GM.
TNF alpha-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPAR gamma without effects on Pref-1 expression.
Endocrinology
138:
2776-2783,
1997
185.
Yasruel, Z,
Cianflore K,
Sniderman AD,
Rosenbloom M,
Walsh MJ,
and
Rodriguez MA.
Effect of acylation stimulating protein on the triacylglycerol synthetic pathway of human adipose tissue.
Lipids
26:
495-499,
1991[ISI][Medline].
186.
Yasukawa, K,
Futatsugi K,
Saito T,
Yawata H,
Narazaki M,
Suzuki H,
Taga T,
and
Kishimoto T.
Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL-6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130.
Immunol Lett
31:
123-130,
1992[ISI][Medline].
187.
Yip, RG,
Boylan MO,
Kieffer TJ,
and
Wolfe MM.
Functional GIP receptors are present on adipocytes.
Endocrinology
139:
4004-4007,
1998
188.
Yip, RG,
and
Wolfe MM.
GIP biology and fat metabolism.
Life Sci
66:
91-103,
2000[ISI][Medline].
189.
Yudkin, JS,
Kumari M,
Humphries SE,
and
Mohamed-Ali V.
Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?
Atherosclerosis
148:
209-214,
2000[ISI][Medline].
190.
Zakrzewska, KE,
Cusin I,
Sainsbury A,
Rohner-Jeanrenaud F,
and
Jeanrenaud B.
Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance.
Diabetes
46:
717-719,
1997[Abstract].
191.
Zemel, MB,
Kim JH,
Woychik RP,
Michaud EJ,
Kadwell SH,
Patel IR,
and
Wilkinson WO.
Agouti regulation of intracellular calcium: role in insulin resistance of viable yellow mice.
Proc Natl Acad Sci USA
92:
4733-4737,
1995[Abstract].
192.
Zhang, B,
Berger J,
Hu E,
Szalkowski D,
White-Carrington S,
Spiegelman BM,
and
Moller DE.
Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-.
Mol Endocrinol
10:
1457-1466,
1996[Abstract].
193.
Zhang, F,
Basinski MB,
Beals JM,
Briggs SL,
Churgay LM,
Clawson DK,
DiMarchi RD,
Furman TC,
Hale JE,
Hsiung HM,
Schoner BE,
Smith DP,
Zhang XY,
Wery JP,
and
Schevitz RW.
Crystal structure of the obese protein leptin-E100.
Nature
387:
206-209,
1997[ISI][Medline].
194.
Zhang, HH,
Kumar S,
Barnett AH,
and
Eggo MC.
Tumour necrosis factor- exerts dual effects on human adipose leptin synthesis and release.
Mol Cell Endocrinol
159:
79-88,
2000[ISI][Medline].
195.
Zhang, Y,
Olbort M,
Schwarzer K,
Nuesslein-Hildesheim B,
Nicolson M,
Murphy E,
Kowalski TJ,
Schmidt I,
and
Leibel RL.
The leptin receptor mediates apparent autocrine regulation of leptin gene expression.
Biochem Biophys Res Commun
240:
492-495,
1997[ISI][Medline].
196.
Zhang, Y,
Proenca R,
Maffei M,
Barone M,
Leopold L,
and
Friedman JM.
Positional cloning of the mouse obese gene and its human homologue.
Nature
372:
425-432,
1994[ISI][Medline].
197.
Zorad, S,
Fickova M,
Zelezna B,
Macho L,
and
Kral JG.
The role of angiotensin II and its receptors in regulation of adipose tissue metabolism and cellularity.
Gen Physiol Biophys
14:
383-391,
1995[ISI][Medline].
198.
Zumbach, MS,
Boehme MWJ,
Wahl P,
Stremmel W,
Ziegler R,
and
Nawroth PP.
Tumor necrosis factor increases serum leptin levels in humans.
J Clin Endocrinol Metab
82:
4080-4082,
1997